Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors

This publication has 20 references indexed in Scilit:

• Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes
  Bioorganic & Medicinal Chemistry, 2009
• The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
  Pharmacological Reviews, 2008
• Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes
  Emerging Drugs, 2008
• The incretin system and its role in type 2 diabetes mellitus
  Published by Elsevier ,2008
• Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials
  Current Medical Research and Opinion, 2008
• The Physiology of Glucagon-like Peptide 1
  Physiological Reviews, 2007
• Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin
  Bioorganic & Medicinal Chemistry Letters, 2007
• Discovery of JANUVIA™ (Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type2 Diabetes.
  Current Topics in Medicinal Chemistry, 2007
• Dipeptidyl peptidase‐IV inhibitors: a major new class of oral antidiabetic drug
  Diabetes, Obesity and Metabolism, 2007
• Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
  Nature Medicine, 2003